Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. Review uri icon

Overview

abstract

  • The immune system plays an essential role in the surveillance and eradication of neoplastic cells. This interaction is modulated via immunologic regulators (checkpoints). Antibodies that block the checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the programmed cell death protein 1 pathway (PD1/PD-L1) have demonstrated efficacy in a number of malignancies. However, response rates are variable, and administration of these antibodies can be associated with immune-related adverse events. Therefore, researchers are engaged in an effort to discover biomarkers that may predict response to these agents. This review focuses on potential blood and tumor-based biomarkers that have been assessed in patients treated with these checkpoint-blocking antibodies.

publication date

  • April 1, 2016

Research

keywords

  • B7-H1 Antigen
  • Biomarkers, Tumor
  • CTLA-4 Antigen
  • Melanoma
  • Programmed Cell Death 1 Receptor

Identity

PubMed Central ID

  • PMC5063308

Scopus Document Identifier

  • 84959272677

Digital Object Identifier (DOI)

  • 10.1007/s11912-016-0509-x

PubMed ID

  • 26922327

Additional Document Info

volume

  • 18

issue

  • 4